USA - NASDAQ:SAVA - US14817C1071 - Common Stock
The current stock price of SAVA is 3.19 USD. In the past month the price decreased by -10.64%. In the past year, price decreased by -88.16%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 40.77 | 848.53B | ||
| JNJ | JOHNSON & JOHNSON | 17.94 | 448.58B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 18.41 | 253.37B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 13.84 | 239.77B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 12.76 | 218.22B | ||
| MRK | MERCK & CO. INC. | 9.36 | 206.04B | ||
| PFE | PFIZER INC | 7.27 | 140.21B | ||
| SNY | SANOFI-ADR | 11.45 | 121.97B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.02 | 93.67B | ||
| GSK | GSK PLC-SPON ADR | 7.64 | 93.22B | ||
| ZTS | ZOETIS INC | 23.21 | 63.97B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 191.71 | 42.38B |
Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. The company is headquartered in Austin, Texas and currently employs 30 full-time employees. The company went IPO on 2000-07-14. The firm's science is based on stabilizing, but not removing, a critical protein in the brain for patients with disorders such as Alzheimer’s disease or TSC. The company has two biopharmaceutical assets under development: Simufilam and SavaDx. Simufilam, its lead therapeutic product candidate, is an oral treatment for Alzheimer’s disease and TSC-related epilepsy. Simufilam targets an altered form of a protein called filamin A (FLNA) in the brain of patients with disorders such as Alzheimer’s disease or TSC. SavaDx, its lead investigational diagnostic product candidate, early-stage program focused on detecting the presence of Alzheimer’s disease from a small sample of blood.
CASSAVA SCIENCES INC
6801 N. Capital of Texas Highway, Building 1
Austin TEXAS 78731 US
CEO: Remi Barbier
Employees: 30
Phone: 15125012444
Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. The company is headquartered in Austin, Texas and currently employs 30 full-time employees. The company went IPO on 2000-07-14. The firm's science is based on stabilizing, but not removing, a critical protein in the brain for patients with disorders such as Alzheimer’s disease or TSC. The company has two biopharmaceutical assets under development: Simufilam and SavaDx. Simufilam, its lead therapeutic product candidate, is an oral treatment for Alzheimer’s disease and TSC-related epilepsy. Simufilam targets an altered form of a protein called filamin A (FLNA) in the brain of patients with disorders such as Alzheimer’s disease or TSC. SavaDx, its lead investigational diagnostic product candidate, early-stage program focused on detecting the presence of Alzheimer’s disease from a small sample of blood.
The current stock price of SAVA is 3.19 USD. The price decreased by -2.15% in the last trading session.
SAVA does not pay a dividend.
SAVA has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
SAVA stock is listed on the Nasdaq exchange.
CASSAVA SCIENCES INC (SAVA) currently has 30 employees.
CASSAVA SCIENCES INC (SAVA) will report earnings on 2025-11-05.
ChartMill assigns a technical rating of 3 / 10 to SAVA. When comparing the yearly performance of all stocks, SAVA is a bad performer in the overall market: 87.85% of all stocks are doing better.
ChartMill assigns a fundamental rating of 2 / 10 to SAVA. While SAVA seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months SAVA reported a non-GAAP Earnings per Share(EPS) of -1.45. The EPS increased by 37.5% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -90.98% | ||
| ROE | -140.01% | ||
| Debt/Equity | 0 |
6 analysts have analysed SAVA and the average price target is 5.1 USD. This implies a price increase of 59.87% is expected in the next year compared to the current price of 3.19.